Gyre Therapeutics (GYRE) Income from Continuing Operations (2010 - 2026)
Gyre Therapeutics (GYRE) reported Income from Continuing Operations of 9858000.0 for Q1 2026, down 364.01% year-over-year from 3734000.0 in Q1 2025, and up 53.04% quarter-over-quarter from 20993000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Income from Continuing Operations data on file, last reported at 9858000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 9858000.0, down 364.01% year-over-year; the trailing twelve-month figure through Mar 2026 was 23339000.0 (down 126.28% YoY), and the FY2025 annual result was 9747000.0, down 136.98% from the prior year.
- Income from Continuing Operations climbed to 9858000.0 in Q1 2026 per GYRE's latest filing, from 20993000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 51632000.0 in Q2 2022 and troughed at 100977000.0 in Q4 2023.
- A 5-year average of 6169647.06 and a median of 2856000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations surged 359.42% in 2022, then plunged 364.01% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 27898000.0 in 2022, then slumped by 261.95% to 100977000.0 in 2023, then soared by 78.77% to 21442000.0 in 2024, then increased by 2.09% to 20993000.0 in 2025, then soared by 53.04% to 9858000.0 in 2026.
- Business Quant data shows GYRE's Income from Continuing Operations at 9858000.0 in Q1 2026, 20993000.0 in Q4 2025, and 5936000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | -20.99 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | -21.44 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | -100.98 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | -27.90 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.22 Mn |
| Jun 30, 2021 | -19.90 Mn |